Navigation Links
Genta Announces Second Quarter 2008 Financial Results and Conference Call
Date:7/31/2008

BERKELEY HEIGHTS, N.J., July 31 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced today that the Company will release its second quarter 2008 financial results on Thursday, August 7, 2008. Genta management will host a conference call and live audio webcast to discuss these financial results and corporate activities at 8:00 am EDT.

Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (706) 679-3140 (International). The access code for the live call is Genta Incorporated. The call will also be webcast live at http://www.genta.com/investorrelation/events.html

For investors unable to participate in the live call, a replay will be available approximately two hours after the completion of the call, and will be archived for 30 days. Access numbers for this replay are: (800) 642-1687 (U.S. and Canada) and (706) 645-9291 (International); conference ID number is 57549066.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment fo
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
2. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
3. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
4. Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
5. Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
6. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
7. Dr. Elizabeth Brown Joins Argenta TEC
8. Syngenta To Build Major Global Biotech Research Center in Beijing, China
9. Genta Restructures Operations to Focus on Priority Initiatives
10. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
11. Auditors for Genta Incorporated Express Going Concern Qualification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
(Date:12/3/2009)Contents of this message: , , Preliminary Press Conference Topics, Last Call! Press Field Trip to California Academy of Sciences museum, Attention PIOs: Sending Press Releases to Fall meeting, N
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Weekend Weather Prompts Air Quality Advisories 54577 1Weekend Weather Prompts Air Quality Advisories 54577 2Weekend Weather Prompts Air Quality Advisories 54577 3The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 1The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 2The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 3The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 4The Dannon Company Awards Cornell Cooperative Extension of Westchester County the Fourth Annual Dannon Next Generation Nutrition Grant 54575 5Senetek PLC Reports Second Quarter 2009 Financial Results 54573 1Senetek PLC Reports Second Quarter 2009 Financial Results 54573 2Senetek PLC Reports Second Quarter 2009 Financial Results 54573 3Senetek PLC Reports Second Quarter 2009 Financial Results 54573 4Senetek PLC Reports Second Quarter 2009 Financial Results 54573 5Senetek PLC Reports Second Quarter 2009 Financial Results 54573 6
GenomePlex Whole Genome Amplification (WGA) kit from Sigma-Aldrich
FluoroGuard Antifade Reagent from Bio-Rad
...n: The greater incorporation of Br-dUTP results in... using a fluorescein-labeled anti-BrdU antibody. ...he kit to counterstain the total DNA. Features and...ting in improved detection than found by using bio...
Mouse Anti-Human FBXO24 Monoclonal Antibody, Unconjugated, Clone 7F12 from Abnova Corporation
Biology Products: